This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
LivaNova (LIVN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of 17.72% and 4.44%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
LivaNova (LIVN) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of 62.22% and 6.45%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Tandem Diabetes Care, Inc. (TNDM) Q1 Earnings Expected to Decline
by Zacks Equity Research
Tandem Diabetes Care (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LivaNova (LIVN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LivaNova (LIVN) Soars 12.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
LivaNova (LIVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
LivaNova (LIVN) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of 10.13% and 6.94%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
CVRx (CVRX) delivered earnings and revenue surprises of 24.56% and 6.93%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
LivaNova (LIVN) Advances Cardiopulmonary Wing With Essenz ILBM
by Zacks Equity Research
LivaNova's (LIVN) Essenz ILBM boasts B-Capta sensing technology, ensuring accuracy and compliance with Clinical Laboratory Improvement Amendments.
LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of 34.48% and 10.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
LivaNova (LIVN) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of 4.88% and 8.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in LivaNova (LIVN): Can Its 12.7% Jump Turn into More Strength?
by Zacks Equity Research
LivaNova (LIVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Here's Why You Should Hold Teladoc Health (TDOC) Stock Now
by Zacks Equity Research
Teladoc Health (TDOC) remains well-poised for growth on the back of solid revenues, sustained demand for virtual care services and sufficient cash-generating abilities.
Neogen (NEOG) Q3 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Neogen (NEOG) delivers core growth in both the Food Safety and Animal Safety segments amid macroeconomic headwinds in the third quarter.
Encompass Health (EHC) Opens JV Hospital for Oklahoma Patients
by Zacks Equity Research
Encompass Health (EHC) inaugurated the Owasso-based Ascension St. John Rehabilitation Hospital, that it will operate jointly with Ascension St. John to offer rehabilitative care in Oklahoma.
LivaNova (LIVN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for LivaNova (LIVN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Orthofix (OFIX) Q4 Earnings Beat Estimates, Gross Margin Dips
by Zacks Equity Research
Orthofix (OFIX) reports impressive performance across the BGT and Global Orthopedics segment in the fourth quarter.
SmileDirectClub (SDC) Q4 Earnings Beat, Gross Margin Down
by Zacks Equity Research
SmileDirectClub (SDC) delivers an improved bottom line and cash flows in the fourth quarter despite a reduction in revenues.
Omnicell (OMCL) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Omnicell (OMCL) delivers earnings and revenues in the fourth quarter exceeding the previously revised outlook amid macroeconomic challenges.
Alcon (ALC) Q4 Earnings Match Estimates, Margins Contract
by Zacks Equity Research
Alcon (ALC) reports impressive CER growth in net sales across all segments in the fourth quarter amid a challenging macroeconomic environment.
Down -12.75% in 4 Weeks, Here's Why You Should You Buy the Dip in LivaNova (LIVN)
by Zacks Equity Research
LivaNova (LIVN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
LivaNova (LIVN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of 12.50% and 4.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Hologic, Inc. (HOLX) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Hologic (HOLX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
HCA Healthcare (HCA) Rises 43% in 6 Months: More Room to Run?
by Zacks Equity Research
HCA Healthcare (HCA) is well-poised for growth due to growing patient volumes, acquisitions and adequate cash-generating abilities.
LivaNova (LIVN) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of 1.75% and 2.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
LivaNova (LIVN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
LivaNova (LIVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.